Detalles de la búsqueda
1.
The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden.
J Med Econ
; 24(1): 447-457, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33754924
2.
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Pharmacoeconomics
; 39(8): 941-952, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34080140
3.
CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
Cancer Res
; 79(1): 47-60, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30385615
Resultados
1 -
3
de 3
1
Próxima >
>>